Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Prevalence of Lipid Abnormalities and Cholesterol Target Value Attainment in Patients with Stable and Acute Coronary Heart Disease in the United Arab Emirates.

Al Mahmeed W, Bakir S, Beshyah SA, Morcos B, Wajih S, Horack M, Lautsch D, Ambegaonkar B, Brudi P, Baxter CA, Vyas A, Gitt AK.

Heart Views. 2019 Apr-Jun;20(2):37-46. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_32_18.

2.

Effect of renal insufficiency and diabetes mellitus on in-hospital mortality after acute coronary syndromes treated with primary PCI. Results from the ALKK PCI Registry.

Liosis S, Hochadel M, Darius H, Behrens S, Mudra H, Lauer B, Elsässer A, Gitt AK, Zahn R, Zeymer U; ALKK study group.

Int J Cardiol. 2019 Oct 1;292:43-49. doi: 10.1016/j.ijcard.2019.04.071. Epub 2019 Apr 25.

PMID:
31088759
3.

Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidemia International Study (DYSIS) II.

Buddhari W, Uerojanaungkul P, Sriratanasathavorn C, Sukonthasarn A, Ambegaonkar B, Brudi P, Horack M, Lautsch D, Vyas A, Gitt AK.

Heart Lung Circ. 2019 Mar 28. pii: S1443-9506(19)30294-X. doi: 10.1016/j.hlc.2019.02.193. [Epub ahead of print]

PMID:
31006593
4.

Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II.

Poh KK, Chin CT, Tong KL, Tan JKB, Lim JS, Yu W, Horack M, Vyas A, Lautsch D, Ambegaonkar B, Brudi P, Gitt AK.

Singapore Med J. 2019 Sep;60(9):454-462. doi: 10.11622/smedj.2019021. Epub 2019 Feb 18.

5.

Incidence and outcome of peri-procedural cardiogenic shock: results from the international Euro Heart Survey PCI registry.

Weipert KF, Bauer T, Nef HM, Hochadel M, Weidinger F, Gitt AK, Zeymer U, Hamm CW.

Eur Heart J Acute Cardiovasc Care. 2019 Jan 8:2048872618822460. doi: 10.1177/2048872618822460. [Epub ahead of print]

PMID:
30618264
6.

Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.

Chuang LH, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Gitt AK, Monreal M, Willich SN, van Hout B.

Qual Life Res. 2019 May;28(5):1155-1177. doi: 10.1007/s11136-018-2081-3. Epub 2019 Jan 3.

PMID:
30607785
7.

Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.

Ferrieres J, De Ferrari GM, Hermans MP, Elisaf M, Toth PP, Horack M, Brudi P, Lautsch D, Bash LD, Baxter CA, Ashton V, Ambegaonkar B, Gitt AK.

Eur J Prev Cardiol. 2018 Dec;25(18):1966-1976. doi: 10.1177/2047487318806359. Epub 2018 Oct 18.

PMID:
30335504
8.

Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II.

Poh KK, Ambegaonkar B, Baxter CA, Brudi P, Buddhari W, Chiang FT, Horack M, Jang Y, Johnson B, Lautsch D, Sawhney J, Vyas A, Yan BP, Gitt AK.

Eur J Prev Cardiol. 2018 Dec;25(18):1950-1963. doi: 10.1177/2047487318798927. Epub 2018 Sep 10.

PMID:
30198749
9.

Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome.

Sobhy M, El Etriby A, El Nashar A, Wajih S, Horack M, Brudi P, Lautsch D, Ambegaonkar B, Vyas A, Gitt AK.

Egypt Heart J. 2018 Sep;70(3):129-134. doi: 10.1016/j.ehj.2018.05.001. Epub 2018 Aug 22.

10.

Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II.

Gitt AK, Rieber J, Hambrecht R, Brachmann J, Graf K, Horack M, Karmann B, Vyas A, Lautsch D, Ambegaonkar B, Brudi P.

Wien Klin Wochenschr. 2018 Dec;130(23-24):707-715. doi: 10.1007/s00508-018-1375-3. Epub 2018 Sep 3.

11.

Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia.

Al Sifri S, Al Shammeri O, Al Jaser S, Alkhenizan A, Bin Shafi Shafiurrehman A, Morcos B, Wajih S, Elnahal I, Horack M, Brudi P, Lautsch D, Ambegaonkar B, Vyas A, Baxter CA, Gitt AK.

Saudi Med J. 2018 Jul;39(7):697-704. doi: 10.15537/smj.2018.7.22146.

12.

Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study.

Ferrières J, Lautsch D, Ambegaonkar BM, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Velkovski-Rouyer M, Horack M, Almahmeed W, Chiang FT, Poh KK, Elisaf M, Brudi P, Gitt AK.

Int J Cardiol. 2018 Nov 1;270:21-27. doi: 10.1016/j.ijcard.2018.06.008. Epub 2018 Jun 6.

13.

Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.

De Ferrari GM, Perna GP, Nicosia A, Guasti L, Casu G, Cuccia C, Picco F, Strazzella C, Totaro R, Cercone S, Canullo L, Horack M, Lautsch D, Gitt AK, Di Biase M.

J Cardiovasc Med (Hagerstown). 2018 Sep;19(9):485-490. doi: 10.2459/JCM.0000000000000680.

PMID:
29917002
14.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2018 May 1;18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun.

15.

Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS).

Ferrières J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, Drexel H, Horack M, Baxter C, Ambegaonkar B, Brudi P, Toth PP.

Diabetes Obes Metab. 2018 Nov;20(11):2670-2674. doi: 10.1111/dom.13415. Epub 2018 Jul 10.

16.

Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II.

Yan BP, Chiang FT, Ambegaonkar B, Brudi P, Horack M, Lautsch D, Vyas A, Gitt AK.

Int J Cardiol. 2018 Aug 15;265:1-5. doi: 10.1016/j.ijcard.2018.01.099.

PMID:
29885676
17.

Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention.

Lautsch D, Gitt AK.

Cardiology. 2018;140(1):68-70. doi: 10.1159/000488972. Epub 2018 Jun 6. No abstract available.

18.

How does the TRS 2°P score relate to real-world patients?

Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrieres J, Gitt AK.

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004. No abstract available.

19.

CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?

Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomström Lundqvist C, Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C, Margitfalvi P, Cano Ó, Plummer C, Sarigul NU, Sterlinski M, Linde C.

Eur J Heart Fail. 2018 Jun;20(6):1039-1051. doi: 10.1002/ejhf.1142. Epub 2018 Feb 19.

20.

Individualised treatment targets in patients with type-2 diabetes and hypertension.

Schmieder RE, Tschöpe D, Koch C, Ouarrak T, Gitt AK; DIALOGUE study group.

Cardiovasc Diabetol. 2018 Jan 22;17(1):18. doi: 10.1186/s12933-018-0661-8.

21.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2017 Nov 14;16:369-375. doi: 10.1016/j.dib.2017.11.034. eCollection 2018 Feb.

22.

Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Atherosclerosis. 2017 Nov;266:158-166. doi: 10.1016/j.atherosclerosis.2017.08.013. Epub 2017 Aug 21.

PMID:
29028484
23.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee.

Thromb Res. 2017 Sep;157:181-188. doi: 10.1016/j.thromres.2017.07.029. Epub 2017 Jul 28.

PMID:
28780343
24.

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT.

Thromb Haemost. 2017 Jun 27;117(7):1326-1337. doi: 10.1160/TH16-10-0793. Epub 2017 Apr 13.

25.

Sex Differences in Percutaneous Coronary Intervention-Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology.

Heer T, Hochadel M, Schmidt K, Mehilli J, Zahn R, Kuck KH, Hamm C, Böhm M, Ertl G, Hoffmeister HM, Sack S, Senges J, Massberg S, Gitt AK, Zeymer U.

J Am Heart Assoc. 2017 Mar 20;6(3). pii: e004972. doi: 10.1161/JAHA.116.004972. Erratum in: J Am Heart Assoc. 2017 Sep 6;6(9):.

26.

Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.

Ferrières J, Rouyer MV, Lautsch D, Ashton V, Ambegaonkar BM, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) II France Study Group.

Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.

27.

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Data Brief. 2016 Sep 29;9:616-620. eCollection 2016 Dec.

28.

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Atherosclerosis. 2016 Dec;255:200-209. doi: 10.1016/j.atherosclerosis.2016.09.004. Epub 2016 Sep 9.

PMID:
27667299
29.

Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies.

Ferrières J, Rouyer MV, Lautsch D, Ambegaonkar BM, Horack M, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) and DYSIS II Study Group.

Int J Cardiol. 2016 Nov 1;222:793-794. doi: 10.1016/j.ijcard.2016.08.084. Epub 2016 Aug 5. No abstract available.

PMID:
27521563
30.

Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.

Catapano AL, Lautsch D, Tokgözoglu L, Ferrieres J, Horack M, Farnier M, Toth PP, Brudi P, Tomassini JE, Ambegaonkar B, Gitt AK.

Atherosclerosis. 2016 Sep;252:1-8. doi: 10.1016/j.atherosclerosis.2016.07.007. Epub 2016 Jul 14.

31.

[Hypercholesterolemia - Where are we today? Where are we going?].

Gitt AK, Zahn R.

Herz. 2016 Aug;41(5):413-20. doi: 10.1007/s00059-016-4457-x. Epub 2016 Jul 13. Review. German.

PMID:
27412663
32.

[Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].

Erbel R, Gitt AK.

Herz. 2016 Jun;41(4):271-2. doi: 10.1007/s00059-016-4442-4. German. No abstract available.

PMID:
27241696
33.

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.

Gitt AK, Bramlage P, Potthoff SA, Baumgart P, Mahfoud F, Buhck H, Ehmen M, Ouarrak T, Senges J, Schmieder RE; EARLY Registry Group.

BMC Cardiovasc Disord. 2016 Mar 8;16:56. doi: 10.1186/s12872-016-0222-6.

34.

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.

Bramlage P, Schmieder RE, Gitt AK, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Potthoff SA; EARLY Registry Group.

Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8.

35.

Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.

Strojek K, Raz I, Jermendy G, Gitt AK, Liu R, Zhang Q, Jacober SJ, Milicevic Z.

J Clin Endocrinol Metab. 2016 Jan;101(1):243-53. doi: 10.1210/jc.2015-1962. Epub 2015 Nov 23.

PMID:
26595100
36.

Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany.

Gitt AK, Sonntag F, Jannowitz C, Weizel A, Karmann B, Schaefer JR, Pittrow D, Hildemann SK.

Curr Med Res Opin. 2016;32(3):417-26. doi: 10.1185/03007995.2015.1120715. Epub 2015 Dec 29.

PMID:
26568400
37.

Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.

Tschöpe D, Bramlage P, Schneider S, Gitt AK.

Diab Vasc Dis Res. 2016 Jan;13(1):2-12. doi: 10.1177/1479164115610470. Epub 2015 Nov 12.

PMID:
26567123
38.

The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.

Agnelli G, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Wolf WP, Cohen AT; PREFER in VTE investigators.

Thromb J. 2015 Oct 21;13:41. doi: 10.1186/s12959-015-0071-z. eCollection 2015.

39.

Use and outcome of thrombus aspiration in patients with primary PCI for acute ST-elevation myocardial infarction: results from the multinational Euro Heart Survey PCI Registry.

Weipert KF, Bauer T, Nef HM, Möllmann H, Hochadel M, Marco J, Weidinger F, Zeymer U, Gitt AK, Hamm CW.

Heart Vessels. 2016 Sep;31(9):1438-45. doi: 10.1007/s00380-015-0754-1. Epub 2015 Oct 5.

PMID:
26438532
40.

Fate of Patients With Coronary Perforation Complicating Percutaneous Coronary Intervention (from the Euro Heart Survey Percutaneous Coronary Intervention Registry).

Bauer T, Boeder N, Nef HM, Möllmann H, Hochadel M, Marco J, Weidinger F, Zeymer U, Gitt AK, Hamm CW.

Am J Cardiol. 2015 Nov 1;116(9):1363-7. doi: 10.1016/j.amjcard.2015.07.056. Epub 2015 Aug 14.

PMID:
26341189
41.

Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort.

Hartmann B, Bramlage P, Schneider S, Tschöpe D, Gitt AK.

Acta Diabetol. 2015 Dec;52(6):1093-101. doi: 10.1007/s00592-015-0794-0. Epub 2015 Aug 5.

PMID:
26239142
42.

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.

Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Senges J, Gitt AK; EARLY Registry Group.

J Clin Hypertens (Greenwich). 2015 Dec;17(12):947-53. doi: 10.1111/jch.12603. Epub 2015 Jun 24.

43.

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.

Schmieder RE, Gitt AK, Koch C, Bramlage P, Ouarrak T, Tschöpe D; DIALOGUE study group.

BMC Endocr Disord. 2015 May 2;15:23. doi: 10.1186/s12902-015-0020-7.

44.

Gender differences in therapeutic recommendation after diagnostic coronary angiography: insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology.

Heer T, Hochadel M, Schmidt K, Mehilli J, Zahn R, Kuck KH, Hamm C, Böhm M, Ertl G, Andresen D, Massberg S, Senges J, Pilz G, Gitt AK, Zeymer U.

Clin Res Cardiol. 2015 Jun;104(6):507-17. doi: 10.1007/s00392-015-0815-6. Epub 2015 Jan 21.

PMID:
25875945
45.

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.

Gitt AK, Bramlage P, Schneider S, Tschöpe D.

Cardiovasc Diabetol. 2015 Feb 3;14:13. doi: 10.1186/s12933-015-0172-9.

46.

Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.

Bramlage P, Gitt AK, Schneider S, Deeg E, Tschöpe D; DiaRegis Study Group.

BMC Cardiovasc Disord. 2014 Nov 19;14:162. doi: 10.1186/1471-2261-14-162.

47.

[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].

Gitt AK, Zahn R.

Herz. 2014 Nov;39(7):798-802. doi: 10.1007/s00059-014-4171-5. German.

PMID:
25361793
48.

Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry.

Monreal M, Bauersachs R, Gitt AK, Laeis P, Mismetti P, Willich SN, Cohen AT, Agnelli G.

Value Health. 2014 Nov;17(7):A504. doi: 10.1016/j.jval.2014.08.1526. Epub 2014 Oct 26. No abstract available.

49.

Treatment Satisfaction In Patients With Venous Thromboembolism As Measured With Pact-Q2: Prefer In Vte Registry.

Willich SN, Bauersachs R, Gitt AK, Mismetti P, Monreal M, Wolf WP, Agnelli G, Cohen AT.

Value Health. 2014 Nov;17(7):A496-7. doi: 10.1016/j.jval.2014.08.1483. Epub 2014 Oct 26. No abstract available.

50.

Health State In Patients With Venous Thromboembolism On Conventional And Non-Vka Oral Anticoagulants As Assessed With The Eq-5d-5l Questionnaire: Prefer In Vte Registry.

Cohen AT, Bauersachs R, Gitt AK, Mismetti P, Monreal M, Willich SN, Wolf WP, Agnelli G.

Value Health. 2014 Nov;17(7):A493-4. doi: 10.1016/j.jval.2014.08.1465. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Support Center